Substitution of the p2 Alanine residue for the optimal Leucine residue (45) produces the peptide ELAGIGILTV which was shown to have considerably higher immunogenicity in vitro (30) and to activate melanoma-reactive CD8 T-cells following vaccination (46). Here, CD8A is linked to melanoma.